Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVID200 in Myelofibrosis
NCT03895112Phase 1Completed
- Sponsor
- John Mascarenhas
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AVID200 in myelofibrosis (MF), sponsored by John Mascarenhas. Primary endpoints: Maximally tolerated dose at 18 weeks and Number of patients with response eligibility for Phase 1b at 18 weeks. Started Feb 2019; status: completed.
02
Drugs
AVID200
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03895112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895112.